TB-500 Alone: Tracking the Thymosin Beta-4 Fragment for Recovery

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring 43-amino-acid protein. The "TB-500" version sold in research peptide markets is a fragment that contains the actin-binding region thought to be responsible for much of the parent molecule's effect on cell migration and tissue repair. There is an existing Peptid AI post on the TB-500/BPC-157 stack — this one is for people running TB-500 alone and need a cleaner tracking framework.

What it does

Thymosin beta-4 binds and sequesters G-actin, which regulates actin polymerization and cell motility. Functionally, that translates to effects on cell migration, angiogenesis, and tissue remodeling. Animal studies show effects on tendon, ligament, cardiac, and dermal healing. Human clinical data is sparse — most evidence comes from preclinical work and self-report.

Typical protocol shape

TB-500 is administered subcutaneously or intramuscularly. Because its tissue effects are slow, weekly or twice-weekly dosing is common rather than daily — a loading phase over several weeks followed by a maintenance phase appears in many protocols. Cycles tend to be longer than for stimulant-style peptides because the outcome metric (tissue healing) is slow.

What to track daily

• Pain at the injury site, 0-10
• Range of motion if relevant
• Any injection-site reaction
• Sleep quality
• Training load on that day

What to track weekly

• Average pain score
• Range of motion change
• Training milestones — first pain-free set, first full-range movement
• Subjective recovery between sessions
• Any new soft tissue niggles elsewhere

Realistic expectations

If you are using TB-500 for an acute soft tissue injury, expect changes over weeks, not days. The signal is gradual reduction in pain at load, improved range, and faster between-session recovery — not a dramatic overnight shift. For chronic injuries that have plateaued, results vary widely and the evidence base is weak. Human RCTs in injury contexts are essentially absent, so honest self-tracking is the best evidence you will have for your own response.

Common mistakes

• Daily dosing when weekly is the typical protocol shape
• Loading up at the start of an acute injury without also adjusting training load
• Continuing to train through pain because the peptide is "working"
• Stacking with BPC-157 from day one, then not knowing which compound did what (this is why a solo run can be informative)
• Sourcing without verifying peptide identity

A tracking template

In Peptid AI, log injection day, site, and dose. Daily: pain at the target site at rest and at load, plus ROM if relevant. Weekly: a training-load summary and an updated pain trend. Monthly: revisit your starting injury rating and write a short qualitative note on what changed. If you also want to compare to a stack later, this solo data becomes your reference baseline.

Safety notes

TB-500 is a research peptide not approved for human use by the FDA or EMA. It is banned by WADA for athletes in tested sport. Long-term safety data in humans is limited, and there is theoretical concern around angiogenic effects in anyone with active malignancy or known proliferative disease — clinician input is appropriate before starting. Sourcing quality varies dramatically; without third-party verification of peptide identity, you are tracking the response to an unknown.

Its regulatory status is also in flux: in April 2026 the FDA removed BPC-157 from the 503A Category 2 list and moved several recovery peptides into a transitional gray zone, and TB-500 - together with BPC-157, KPV, and MOTS-C - is on the agenda for the Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 that will decide whether they can be legally compounded. Expect this landscape to keep shifting through 2026.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.